Kevin Kunzmann

Patients who abused substances reported significantly greater cardiovascular and all-cause mortality risk from type 1 MI — despite also reporting lower risks for traditional factors.

Astellas Pharma's mirabegron (Mybetriq) will serve as a combination therapy with muscarinic antagonist solifenacin succinate (VESIcare) for the treatment of overactive bladder in patients with particular symptoms.

Women who consumed fruit just 1-3 times per month versus those that consumed it at least 3 times daily corresponded to a 19% increase in median time to pregnancy.

Hemospray, from Wilson-Cook Medical, stopped GI bleeding in nearly all patients within 5 minutes of treatment.

PLENVU, a one-liter solution from Salix Pharmaceuticals, is expected to reach US markets by the third quarter of 2018.

An analysis of 350,000-plus veterans found those who suffered concussions have at least a 2.51-fold increased risk of developing dementia.

The Group Medical Director of Neuroscience at Genentech discussed the drug's background, which has evolved into continued multi-year trials.

The investigative vaccine from PaxVax is a virus-like particle currently undergoing phase 2B analysis for dosage rates.

An injectable soluble formulation of naturally-secreted growth factors developed by Histogen will begin its first company-sponsored clinical trial.

A massive genetic family migraine patient study found more defined risk scores for migraine subtypes.

The discovery could have researchers reconsidering treatment routes for pediatric patients.

Genentech's global head of Neuroscience clinical development detailed the company's commitment to treating the progressive form of multiple sclerosis.

The Computed Tomography Angiography device from iSchemaView gives physicians quick, and diverse, options to analyze stroke patient candidates.

Montes' team found benefits in motor function, walking ability, and fatigue in patients to undergo nusinersen (Spinraza) for spinal muscular atrophy.

The Global Head of Neurodegeneration for Genentech talks about the progress of 2 promising monoclonal antibodies.

The vice president of Development Sciences for Biogen shared developments to come of the international MS PATHS collaboration.

How an Australian anesthetist and English midwife student convinced providers around the world to be open about their names.

Patients from 2 demographically-different studies switching from interferon therapy to Aubagio reported similar improvements.

The executive vice president and chief medical officer of Biogen explained how crucial it is for potential DMTs to attacki the alpha-synuclein protein.

The director of the Sports Neurology Program at Norton Healthcare and head of the NCAA Headache Task Force discussed trends in his popularizing field.

Results from Alder Biopharmaceutical’s phase 3 study demonstrated reductions in migraine following quarterly infusions of both 100 mg and 300 mg eptinezumab versus placebo in patients with episodic migraines.

Lead author Alexander D. Rae-Grant, MD, explains the measures taken to ensure the panel got their 16-year multiple sclerosis recommendations update right.

Already tasked with a burdensome regimen of therapy for nerve damage, some patients may just be looking for simpler relief.

The investigative therapy for SMA reported various efficacy results in a phase 3 extension trial.

A new study finding that 50% of low income Latino patients with MS suffer from depression is coupled with recent reports on their exclusion from clinical research.

How a litany of treatment options could be just a single breakthrough drug away.

How the brain processes thought and action can be heavily influenced by the size of the network it's exposed to.

The investigatory therapy for secondary progressive MS returned even more promising post hoc analysis prior to its FDA consideration.

The 10,000-plus participant IMPACT study reported the triple-combination therapy fared better in exacerbation reduction than FF/VI or FF/UMEC.

An analysis of 40-plus trials report that the closed loop system care can be the difference in 2.5 extra hours of daily normoglycemia.